|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's range||139.29 - 148.21|
|52-week range||41.66 - 169.54|
|Beta (5Y monthly)||1.50|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||170.25|
Earlier today, iRhythm released financial results for the second quarter ended June 30, 2022. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements.
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 15.96% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2022. Second Quarter 2022 Financial Highlights Revenue of $102.1 million, a 25.6% increase compared to second quarter 2021Gross margin of 68.8%, a 0.8 percentage point improvement compared to second quarter 2021Cash and short-term investments of $2